WaferGen Q2 Revenues Down 6 Percent on Reduced SmartChip Sales | GenomeWeb

This article has been updated to include comments from WaferGen's conference call following the release of results.


NEW YORK (GenomeWeb) - WaferGen Biosystems reported after the close of the market Wednesday that its second quarter revenues fell 6 percent due to reduced SmartChip capital equipment sales.

For the three months ended June 30, the genetic analysis products maker reported total revenues of $1.6 million, compared to $1.7 million in Q2 2014 and short of the consensus analysts' estimate of $2.1 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Startup companies are taking on personalized medicine, CNET reports.

Bruce Booth writes at Life Sci VC that biotech clusters like Boston and San Francisco are getting even more consolidated.

The Verge speaks with Mark and Scott Kelly, who are the subjects of NASA's Twin Study.

In Genome Biology this week: genes linked to Hirschsprung disease, structural variant patterns in autism, and more.